Indapamide for Arterial Hypertension
Indapamide is appropriate as first-line therapy for arterial hypertension in adults, with a recommended starting dose of 1.25 mg once daily, titrating to a maximum of 2.5 mg daily if needed. 1, 2, 3
First-Line Appropriateness
Indapamide, a thiazide-like diuretic, is explicitly recommended as first-line monotherapy for uncomplicated hypertension across multiple major guidelines 1, 2. Thiazide-like diuretics (indapamide and chlorthalidone) are now preferred over traditional thiazides (hydrochlorothiazide) because they provide superior cardiovascular protection 2. A meta-analysis of 21 randomized controlled trials demonstrated that thiazide-like diuretics resulted in an additional 12% risk reduction for cardiovascular events (p=0.049) and 21% risk reduction in heart failure (p=0.023) compared with thiazide diuretics 2. Only thiazide-like diuretics reduced the risk of coronary events and all-cause mortality when compared to placebo 2.
The 2020 Hypertension Canada guidelines specifically list longer-acting thiazide-like diuretics as preferred first-line agents (Grade A evidence) 1. The 2024 ESC guidelines and 2020 ISH guidelines similarly endorse thiazide/thiazide-like diuretics as one of the four major first-line drug classes 4, 5.
Recommended Dosage
For hypertension, start with indapamide 1.25 mg once daily in the morning 3. If blood pressure response is inadequate after 4 weeks, increase to 2.5 mg once daily 3. If still inadequate after another 4 weeks at 2.5 mg, increase to 5 mg once daily, though adding another antihypertensive agent should be strongly considered at this point 3.
Clinical pharmacology data shows that doses of 2.5 mg and 5 mg produce similar antihypertensive effects but higher doses are associated with greater hypokalemia 3. The drug reaches peak blood concentrations within 2 hours and has a half-life of approximately 14 hours, supporting once-daily dosing 3.
Contraindications and Precautions
Absolute contraindications include:
- Anuria or severe renal impairment
- Hypersensitivity to sulfonamide-derived drugs
- Severe hepatic impairment with encephalopathy
Use with caution in:
- Patients with gout or hyperuricemia (indapamide increases uric acid by approximately 0.69-1 mg/100 mL) 3
- Elderly patients, particularly those who are frail 1, 6
- Patients at risk for hypokalemia (baseline potassium should be >4.5 mmol/L before initiating therapy) 1
Do not combine with:
- Other potassium-depleting agents without careful monitoring
- Lithium (increased risk of lithium toxicity)
Monitoring Requirements
Before initiating therapy:
- Baseline serum potassium (should be >4.5 mmol/L) 1
- Baseline renal function (serum creatinine, eGFR)
- Baseline uric acid level
- Baseline sodium level
During therapy:
- Recheck electrolytes and renal function 2-4 weeks after initiation 7, 8
- Monitor blood pressure response at 4 weeks 3
- Ongoing monitoring of serum potassium, particularly if combining with ACE inhibitors or ARBs 1
- Monitor for hypokalemia (mean decrease of 0.28-0.76 mEq/L depending on dose) 3
- Monitor uric acid levels, especially in patients with history of gout 3
Target blood pressure: Achieve <140/90 mm Hg for most patients, with more intensive targets (<130/80 mm Hg) for high-risk patients with cardiovascular disease, chronic kidney disease, diabetes, or age ≥75 years 1, 5.
Combination Therapy Considerations
If blood pressure remains uncontrolled on indapamide monotherapy, add an ACE inhibitor, ARB, or calcium channel blocker rather than increasing indapamide beyond 2.5 mg 1, 3. The combination of indapamide with an ACE inhibitor or ARB is particularly effective and well-studied 2, 9, 10. Single-pill combinations are preferred when available to improve adherence 4.
For stage 2 hypertension (≥160/100 mm Hg), consider initiating with dual therapy immediately using indapamide plus an ACE inhibitor/ARB or calcium channel blocker 11, 7, 8.
Special Populations
Very elderly (≥80 years): The HYVET trial used indapamide 1.5 mg (sustained release formulation) with or without perindopril in patients ≥80 years, demonstrating reduced stroke and all-cause mortality 6, 12. Start treatment when SBP ≥160 mm Hg with a target <150 mm Hg 6, 12.
Isolated systolic hypertension: Indapamide is specifically recommended as first-line monotherapy (Grade A) 12.
Common Pitfalls to Avoid
- Don't use hydrochlorothiazide when indapamide is available - thiazide-like diuretics provide superior cardiovascular protection 2
- Don't increase indapamide beyond 2.5 mg without adding a second agent - higher doses increase side effects without proportional benefit 3
- Don't forget to monitor potassium - hypokalemia is the most common metabolic side effect and should be avoided 1, 12
- Don't overlook uric acid monitoring - particularly important in patients with gout history 3